Search - tctmd.com

Displaying 1 - 20 of 125

Sort: Relevancy | Date

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

L.A. McKeown

December 12, 2018

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

Yael L. Maxwell

December 05, 2018

News Daily News

Global Investigative Journalism Initiative Takes Aim at Medical Device Industry

Todd Neale

November 26, 2018

News Daily News

FDA Touts Increased Oversight of Medical Device Makers

Michael O'Riordan

November 22, 2018

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

L.A. McKeown

November 08, 2018

News Industry News

4TECH Inc. Reports First U.S. Clinical Implantations of Its TriCinch™ Coil Tricuspid Valve Repair System

November 07, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

Todd Neale

November 01, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

Michael O'Riordan

October 19, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

Advertisement

The Biggest News of 2018: TCTMD’s Top 10

Top News in Endovascular Therapy: 2018

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Hospitals With Higher SAVR Mortality Likely to Have Higher TAVR Mortality, Too

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

FDA Advisors Give Blessing to Implantable Pulse Generator in Certain Heart Failure Patients

Global Investigative Journalism Initiative Takes Aim at Medical Device Industry

FDA Touts Increased Oversight of Medical Device Makers

Complications Following TAVR Are Going Down, US Data Show

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

4TECH Inc. Reports First U.S. Clinical Implantations of Its TriCinch™ Coil Tricuspid Valve Repair System

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content